Greg Perry Resigns As Director Of Medicines Patent Pool 14/12/2017 William New After nearly five years as the executive director of the Medicines Patent Pool, Greg Perry has stepped down with little notice. [Update: the next day, it was announced that he has joined the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) in Geneva.] Continue reading -> WTO General Council Agrees To 2-Year Extension For TRIPS Health Amendment Acceptance 30/11/2017 William New The World Trade Organization General Council today agreed to a two-year extension for countries to adopt an amendment to the agency's intellectual property agreement intended to help small economies get affordable medical products. But a decision on non-violation complaints will be left to the December WTO ministerial in Buenos Aires. Continue reading -> WHO Issues Two Reports Detailing Global Problem Of Substandard And Falsified Medicines 28/11/2017 William New The World Health Organization today issued two substantive reports on the problem of substandard and falsified medicines around the world, finding among other things that an estimated one in 10 medical products in low and middle income countries is either substandard or falsified. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> ‘Damaging’ Provisions On IP Dropped From TPP Agreement, MSF Says 15/11/2017 William New Trade ministers negotiating the Trans-Pacific Partnership (TPP) without the United States have dropped many problematic provisions related to intellectual property and health, Médicins Sans Frontières (MSF, Doctors Without Borders) reported today. Also removed from the agreement appears to be the investor-state dispute settlement provisions, according to a source. Continue reading -> Global Fund Chooses Former UK Banker Peter Sands As New Director 14/11/2017 William New The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria today selected Peter Sands, a former bank CEO who is involved in health projects at the World Bank and elsewhere, as its next executive director. Continue reading -> As Global Fund Board Meets To Choose New Director, Sands Seeks To Reinstate Candidacy 13/11/2017 William New Days after withdrawing from consideration to be the next director of the Global Fund for AIDS, Tuberculosis and Malaria, the UK's Peter Sands has asked to be reinstated. The actions come as the Fund's Board gathers this week to choose among the final candidates for head of the international health funding organisation based in Geneva. Continue reading -> UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WTO General Council Agrees To 2-Year Extension For TRIPS Health Amendment Acceptance 30/11/2017 William New The World Trade Organization General Council today agreed to a two-year extension for countries to adopt an amendment to the agency's intellectual property agreement intended to help small economies get affordable medical products. But a decision on non-violation complaints will be left to the December WTO ministerial in Buenos Aires. Continue reading -> WHO Issues Two Reports Detailing Global Problem Of Substandard And Falsified Medicines 28/11/2017 William New The World Health Organization today issued two substantive reports on the problem of substandard and falsified medicines around the world, finding among other things that an estimated one in 10 medical products in low and middle income countries is either substandard or falsified. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> ‘Damaging’ Provisions On IP Dropped From TPP Agreement, MSF Says 15/11/2017 William New Trade ministers negotiating the Trans-Pacific Partnership (TPP) without the United States have dropped many problematic provisions related to intellectual property and health, Médicins Sans Frontières (MSF, Doctors Without Borders) reported today. Also removed from the agreement appears to be the investor-state dispute settlement provisions, according to a source. Continue reading -> Global Fund Chooses Former UK Banker Peter Sands As New Director 14/11/2017 William New The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria today selected Peter Sands, a former bank CEO who is involved in health projects at the World Bank and elsewhere, as its next executive director. Continue reading -> As Global Fund Board Meets To Choose New Director, Sands Seeks To Reinstate Candidacy 13/11/2017 William New Days after withdrawing from consideration to be the next director of the Global Fund for AIDS, Tuberculosis and Malaria, the UK's Peter Sands has asked to be reinstated. The actions come as the Fund's Board gathers this week to choose among the final candidates for head of the international health funding organisation based in Geneva. Continue reading -> UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
WHO Issues Two Reports Detailing Global Problem Of Substandard And Falsified Medicines 28/11/2017 William New The World Health Organization today issued two substantive reports on the problem of substandard and falsified medicines around the world, finding among other things that an estimated one in 10 medical products in low and middle income countries is either substandard or falsified. Continue reading -> Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> ‘Damaging’ Provisions On IP Dropped From TPP Agreement, MSF Says 15/11/2017 William New Trade ministers negotiating the Trans-Pacific Partnership (TPP) without the United States have dropped many problematic provisions related to intellectual property and health, Médicins Sans Frontières (MSF, Doctors Without Borders) reported today. Also removed from the agreement appears to be the investor-state dispute settlement provisions, according to a source. Continue reading -> Global Fund Chooses Former UK Banker Peter Sands As New Director 14/11/2017 William New The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria today selected Peter Sands, a former bank CEO who is involved in health projects at the World Bank and elsewhere, as its next executive director. Continue reading -> As Global Fund Board Meets To Choose New Director, Sands Seeks To Reinstate Candidacy 13/11/2017 William New Days after withdrawing from consideration to be the next director of the Global Fund for AIDS, Tuberculosis and Malaria, the UK's Peter Sands has asked to be reinstated. The actions come as the Fund's Board gathers this week to choose among the final candidates for head of the international health funding organisation based in Geneva. Continue reading -> UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Industry Urges UK, EU, To Safeguard Medicines Regulation During Post-Brexit Transition 28/11/2017 William New Associations representing the life sciences industry in the United Kingdom and Europe today issued a call for cooperation on regulation between the UK and European Union on medicines regulation. Continue reading -> US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> ‘Damaging’ Provisions On IP Dropped From TPP Agreement, MSF Says 15/11/2017 William New Trade ministers negotiating the Trans-Pacific Partnership (TPP) without the United States have dropped many problematic provisions related to intellectual property and health, Médicins Sans Frontières (MSF, Doctors Without Borders) reported today. Also removed from the agreement appears to be the investor-state dispute settlement provisions, according to a source. Continue reading -> Global Fund Chooses Former UK Banker Peter Sands As New Director 14/11/2017 William New The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria today selected Peter Sands, a former bank CEO who is involved in health projects at the World Bank and elsewhere, as its next executive director. Continue reading -> As Global Fund Board Meets To Choose New Director, Sands Seeks To Reinstate Candidacy 13/11/2017 William New Days after withdrawing from consideration to be the next director of the Global Fund for AIDS, Tuberculosis and Malaria, the UK's Peter Sands has asked to be reinstated. The actions come as the Fund's Board gathers this week to choose among the final candidates for head of the international health funding organisation based in Geneva. Continue reading -> UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
US NAFTA Negotiating Objectives For IP: Go Big On Digital IP Protection, Fend Off GIs 20/11/2017 William New The Office of the United States Trade Representative (USTR) has issued a set of negotiating objectives for renegotiating the 1994 North American Free Trade Agreement (NAFTA) that include its hopes for elevating intellectual property in the trade deal. Included in the list: force Canada and Mexico to ratify international treaties, accept US law on IP protection and create conditions for "strong" IP enforcement especially online, and ensure ample protection for products with generic names. Perhaps oddly, there is only one mention of trade, which includes respect for a 2001 text at the World Trade Organization on IP and public health. Continue reading -> ‘Damaging’ Provisions On IP Dropped From TPP Agreement, MSF Says 15/11/2017 William New Trade ministers negotiating the Trans-Pacific Partnership (TPP) without the United States have dropped many problematic provisions related to intellectual property and health, Médicins Sans Frontières (MSF, Doctors Without Borders) reported today. Also removed from the agreement appears to be the investor-state dispute settlement provisions, according to a source. Continue reading -> Global Fund Chooses Former UK Banker Peter Sands As New Director 14/11/2017 William New The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria today selected Peter Sands, a former bank CEO who is involved in health projects at the World Bank and elsewhere, as its next executive director. Continue reading -> As Global Fund Board Meets To Choose New Director, Sands Seeks To Reinstate Candidacy 13/11/2017 William New Days after withdrawing from consideration to be the next director of the Global Fund for AIDS, Tuberculosis and Malaria, the UK's Peter Sands has asked to be reinstated. The actions come as the Fund's Board gathers this week to choose among the final candidates for head of the international health funding organisation based in Geneva. Continue reading -> UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
‘Damaging’ Provisions On IP Dropped From TPP Agreement, MSF Says 15/11/2017 William New Trade ministers negotiating the Trans-Pacific Partnership (TPP) without the United States have dropped many problematic provisions related to intellectual property and health, Médicins Sans Frontières (MSF, Doctors Without Borders) reported today. Also removed from the agreement appears to be the investor-state dispute settlement provisions, according to a source. Continue reading -> Global Fund Chooses Former UK Banker Peter Sands As New Director 14/11/2017 William New The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria today selected Peter Sands, a former bank CEO who is involved in health projects at the World Bank and elsewhere, as its next executive director. Continue reading -> As Global Fund Board Meets To Choose New Director, Sands Seeks To Reinstate Candidacy 13/11/2017 William New Days after withdrawing from consideration to be the next director of the Global Fund for AIDS, Tuberculosis and Malaria, the UK's Peter Sands has asked to be reinstated. The actions come as the Fund's Board gathers this week to choose among the final candidates for head of the international health funding organisation based in Geneva. Continue reading -> UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
Global Fund Chooses Former UK Banker Peter Sands As New Director 14/11/2017 William New The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria today selected Peter Sands, a former bank CEO who is involved in health projects at the World Bank and elsewhere, as its next executive director. Continue reading -> As Global Fund Board Meets To Choose New Director, Sands Seeks To Reinstate Candidacy 13/11/2017 William New Days after withdrawing from consideration to be the next director of the Global Fund for AIDS, Tuberculosis and Malaria, the UK's Peter Sands has asked to be reinstated. The actions come as the Fund's Board gathers this week to choose among the final candidates for head of the international health funding organisation based in Geneva. Continue reading -> UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
As Global Fund Board Meets To Choose New Director, Sands Seeks To Reinstate Candidacy 13/11/2017 William New Days after withdrawing from consideration to be the next director of the Global Fund for AIDS, Tuberculosis and Malaria, the UK's Peter Sands has asked to be reinstated. The actions come as the Fund's Board gathers this week to choose among the final candidates for head of the international health funding organisation based in Geneva. Continue reading -> UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
UNCTAD Shows Role As Convenor On Investment In Antimicrobial Resistance 30/10/2017 William New The United Nations Conference on Trade and Development (UNCTAD) this month gathered a wide range of key stakeholders to have a frank discussion about how to solve rising global resistance to existing antibiotics. While not a negotiation, stakeholders in the expert group opened up and shared perspectives, leading to some informal conclusions. Among them: more public and private investment, and a shift in the R&D system to new-style incentives, are needed. Continue reading -> CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
CARB-X Makes Award For First Topical Antimicrobial; Could Be Used In Emergency Settings 24/10/2017 William New CARB-X, an initiative aimed at accelerating innovation in antibacterial treatment, today announced an award to a company to accelerate development of a new bioengineered antimicrobial intended to be applied directly to affected tissues. This follows an announcement earlier this month of funding another firm to develop a new antibiotic class to treat drug-resistant Gram-negative bacterial infections. Continue reading -> Posts navigation Older postsNewer posts